About Mirvie
Mirvie is a healthcare AI company dedicated to transforming pregnancy health through the early prediction of complications. Their proprietary Mirvie RNA platform utilizes a simple blood test to analyze tens of thousands of RNA messages from the mother, placenta, and baby. By applying advanced machine learning and AI to this transcriptomic data, the platform can detect the underlying biological drivers of various pregnancy complications, such as preeclampsia, preterm birth, and fetal growth restriction, months before symptoms appear.
This innovative approach aims to shift prenatal care from a reactive, crisis-management model to a proactive, preventive, and personalized one. For physicians, this means having vital, actionable information about a pregnancy’s unique biology, enabling earlier interventions and tailored care plans to improve outcomes for both mothers and babies. Mirvie’s Encompass™ test, for example, is designed to predict the risk of preeclampsia, with studies showing its ability to identify a significant percentage of women who will develop the condition months in advance.
Focus Areas
Business Intelligence
| Key Investors | Portfolia, Gates Foundation, BlackRock, Decheng Capital, Foresite Capital, General Catalyst, GV, Khosla Ventures, Mayfield, Comerica Bank, Allyson Felix |
| Partnerships | Advantia Health, WIN (Women's Integrated Network) |
| Technology | The Mirvie RNA Platform combines advanced transcriptomic analysis of tens of thousands of RNA messages from the baby, placenta, and mother with machine learning and AI. This platform, utilizing a simple blood test, reveals vital information about a pregnancy's unique biology to predict complications months before they occur. |
| FDA Clearances | 1 (Breakthrough Device Designation for preeclampsia test) cleared products (estimated) |
What Physicians Need to Know
Mirvie's predictive tests, such as the Encompassu2122 test for preeclampsia, offer physicians the ability to identify high-risk pregnancies months in advance, enabling the implementation of evidence-based prevention care plans, such as low-dose aspirin and close clinical management. This shifts prenatal care from a reactive 'wait and see' approach to a proactive and personalized model, potentially delaying onset or preventing severe complications. The platform also provides a deeper understanding of the underlying biology of pregnancy complications, which can lead to more precise and personalized interventions.
Mirvie is actively partnering with healthcare providers and benefits providers to integrate their predictive testing into maternal health programs. For example, they have launched a pilot program with Advantia Health to improve pregnancy outcomes using the Encompass Preeclampsia Test. They are also partnering with WIN, a family-building and family wellness benefits provider, to offer the Encompass test as part of an expanded maternal health solution. These collaborations aim to facilitate early preventive care interventions and provide individualized support to pregnant women.
What the Web Says
Mirvie is a company developing a medical diagnostic platform that uses RNA sequencing and machine learning to predict pregnancy complications like preeclampsia and preterm birth months before symptoms appear. Their first commercial product, Encompass, launched in 2025 and focuses on predicting preeclampsia risk. The company aims to transform prenatal care from reactive to proactive by providing clinicians and expectant mothers with early risk assessment and personalized action plans.
Overall: PositiveStrengths
- Predicts pregnancy complications months in advance, allowing for proactive intervention.
- Utilizes advanced RNA platform and machine learning for a deeper understanding of pregnancy biology.
- Encompass test shows high probability of not developing preterm preeclampsia with a low-risk result (99.7%).
- Backed by significant clinical studies and peer-reviewed research.
- Positive employee reviews mention a great work environment, supportive management, and exciting work.
- Offers a direct-to-consumer online purchase process with telehealth clinician review and mobile phlebotomy.
Limitations
- As a startup, there's a risk of constant changes and potential layoffs.
- The underlying studies are company-sponsored, which, while peer-reviewed, is noted as a factor to consider.
- The product is sold with a virtual assistant, raising questions about automated systems conversing with pregnant women about serious conditions.
- Lack of randomized comparison against standard care means no direct evidence yet that acting on the result changes outcomes.
- Test has not yet been adopted into national guidelines.
- No breakdown of test performance by race or ethnicity, which is crucial given racial disparities in maternal mortality.
Based on reviews from: Indeed.com, AI Health Index, PitchBook, Forbes, Mirvie.com, Reddit, Business Wire, Femtech Insider
Last updated: 2026-08-24
Videos
News, demos, and interviews about Mirvie.
Videos load interactively. If none appear, search YouTube for Mirvie →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Mirvie.
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]